Investor Presentaiton
Best change from baseline in sum of diameters, %
DS-6000
Ovarian cancer/renal cell carcinoma Ph1 data
ASCO 2022 Highlights
Tolerability and preliminary efficacy were observed in the interim Ph1 data
■DS-6000 was generally well tolerated
Daiichi-Sankyo
DS-6000 demonstrated early clinical signals (RECIST and CA-125 responses) in heavily pretreated patients with advanced platinum-resistant
OVC and RCC
■Expansion cohorts (part B) opened at 8.0 mg/kg are enrolling patients with OVC and RCC
Anti-tumor activity (OVC, RCC)
Change from baseline in CA-125* levels
in patients with OVCa
80-
60-
RCC renal cell carcinoma OVC = serous ovarian cancer
40-
20-
4.8 mg/kg
8.0 mg/kg
OVC OVC RCC OVC OVC RCC OVC OVC OVC OVC OVC RCC OVC
0
RCC OVC OVC RCC OVC RCC OVC
-20-
-40-
-60-
-80-
Best change from baseline in CA-125, %
80
60
SD
40
PD
20-
b b b b b b
b
b
0
SD
NA
PR
-20
-40
-60-
-80
PR
SD
Non-CR/
Non-PD SD
SD
SD PR SD Non-CR/
-100
Non-PD PR
SD PR
-100-
Starting dose level 1.6 mg/kg 3.2 mg/kg 4.8 mg/kg 6.4 mg/kg
18.0 mg/kg
19.6 mg/kg
Starting dose level
1.6 mg/kg 3.2 mg/kg 4.8 mg/kg 6.4 mg/kg 8.0 mg/kg 9.6 mg/kg
Data cutoff: February 25, 2022.
CA-125, cancer antigen 125; CR, complete response; GCIG, Gynecologic Cancer InterGroup; NA, not available; OVC, ovarian cancer; PD, progressive disease; PR, partial response; SD, stable disease.
a Patients with baseline CA-125 value and ≥1 postbaseline CA-125 value were included.
b According to the GCIG criteria, patients can be evaluated for response only if they have a baseline sample that is ≥2 x the upper limit of normal obtained within 2 weeks prior to starting treatment. CA-125 response is defined as a ≥50% reduction in CA-125 levels from a pretreatment sample.
The response must be confirmed and maintained for ≥28 days.
*CA-125: Protein which express on endometrium and peritoneum. CA-125 level in blood increases in patients with gynopathy such as ovarian cancer and uterine cancer.
30View entire presentation